A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Active, not recruiting · NCT02852655 · Registry updated 2026-03-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma | Neoplasms by Site, brain cancer, brain disorder, central nervous system cancer, central nervous system disorder, neoplasm, nervous system disorder | Active, not recruiting | Phase 1 | 2026-03-20 | NCT02852655 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| Merck Sharp & Dohme LLC | 650 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 133 |
| Huntsman Cancer Institute | Salt Lake City | United States | 107 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Memorial Sloan-Kettering Cancer | New York | United States | 2 |
| University of California, Los Angeles | Los Angeles | United States | 142 |
| University of California, San Francisco | San Francisco | United States | 2 |
| UT, MD Anderson Cancer Center | Houston | United States | 1 |